President Donald Trump has received an experimental drug following his diagnosis of Covid-19, the White House said Friday.
The drug cocktail is a combination of two so-called monoclonal antibodies. The treatment is meant to provide the body’s immune system with a temporary but immediate boost to fight off the coronavirus.
Monoclonal antibodies are made in a lab to mimic the body’s natural antibodies. Antibodies act by recognizing specific germs — in this case, SARS-CoV-2, the virus that causes Covid-19 — and harnessing the immune system to fight them off.
The therapy, though still unproven, is considered by experts to be one of the most promising treatment options for the illness.
Regeneron confirmed it provided its drug to the president under what is called “compassionate use,” through which the Food and Drug Administration allows access to experimental drugs outside of clinical trials for patients with life-threatening conditions or serious diseases.
Download the NBC News app for full coverage of the coronavirus outbreak
The treatment is being studied in clinical trials as a potential treatment for and possible prevention of illness in people who have been exposed. The drug company said Tuesday that early evidence from the trials suggest that the treatment appears to be beneficial in patients with mild to moderate illness.
“It decreased viral load and made symptoms resolve faster,” said Dr. Todd Rice, an associate professor of medicine at Vanderbilt University Medical Center in Nashville, Tennessee. Rice is not involved with Regeneron’s clinical trials.
The letter from the president’s physician also said Trump has been taking zinc, vitamin D, the heartburn drug famotidine, a daily aspirin and a sleep aid called melatonin. All of those are sold over the counter. There is no solid evidence that any might help treat Covid-19.
CLARIFICATION (Oct. 4, 2020, 10:34 a.m. ET): An earlier version of this article quoted a White House physician as saying that the president on Friday received “a single 8-gram dose of Regeneron’s polyclonal antibody cocktail.” The drugmaker Regeneron later told NBC News that Trump received a combination of two monoclonal antibodies, not one. The article has been updated.